AU2021308208A1 - SARS-CoV-2 inhibitors - Google Patents

SARS-CoV-2 inhibitors Download PDF

Info

Publication number
AU2021308208A1
AU2021308208A1 AU2021308208A AU2021308208A AU2021308208A1 AU 2021308208 A1 AU2021308208 A1 AU 2021308208A1 AU 2021308208 A AU2021308208 A AU 2021308208A AU 2021308208 A AU2021308208 A AU 2021308208A AU 2021308208 A1 AU2021308208 A1 AU 2021308208A1
Authority
AU
Australia
Prior art keywords
amino acid
acid sequence
polypeptide
seq
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021308208A
Other languages
English (en)
Inventor
David Baker
John Bowen
Scott BOYKEN
Longxing CAO
Lauren Carter
James Brett CASE
Brian COVENTRY
Michael Diamond
Natasha EDMAN
Inna GORESHNIK
Andrew Hunt
Michael Christopher Jewett
Lisa KOZODOY
Lauren Miller
Cassandra Jean OGOHARA
Young-Jun Park
Rashmi RAVICHANDRAN
Lance Joseph STEWART
George Ueda
David VEESLER
Bastian VOGELI
Alexandra C. WALLS
Kejia WU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Northwestern University
Washington University in St Louis WUSTL
Original Assignee
University of Washington
Northwestern University
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington, Northwestern University, Washington University in St Louis WUSTL filed Critical University of Washington
Publication of AU2021308208A1 publication Critical patent/AU2021308208A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
AU2021308208A 2020-07-14 2021-05-25 SARS-CoV-2 inhibitors Pending AU2021308208A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063051474P 2020-07-14 2020-07-14
US63/051,474 2020-07-14
US202063067593P 2020-08-19 2020-08-19
US63/067,593 2020-08-19
PCT/US2021/034069 WO2022015418A1 (en) 2020-07-14 2021-05-25 Sars-cov-2 inhibitors

Publications (1)

Publication Number Publication Date
AU2021308208A1 true AU2021308208A1 (en) 2023-01-05

Family

ID=76808129

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021308208A Pending AU2021308208A1 (en) 2020-07-14 2021-05-25 SARS-CoV-2 inhibitors

Country Status (7)

Country Link
US (1) US20230250134A1 (https=)
EP (1) EP4182027A1 (https=)
JP (2) JP2023542453A (https=)
KR (1) KR20230038485A (https=)
CN (1) CN116209672A (https=)
AU (1) AU2021308208A1 (https=)
WO (1) WO2022015418A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240309059A1 (en) * 2021-07-07 2024-09-19 National University Corporation Tokyo Medical And Dental University Peptide having anti-viral activity, anti-viral agent comprising said peptide, and method for producing said anti-viral agent
KR20240177843A (ko) * 2023-06-20 2024-12-30 주식회사 엔큐라젠 SARS-CoV-2스파이크 단백질에 특이적으로 결합하는 펩타이드 및 이의 용도
WO2025101453A1 (en) * 2023-11-07 2025-05-15 University Of Washington De novo design of potent minibinder antagonists of il-6r, gp130, and il1-r1
WO2025221716A1 (en) * 2024-04-17 2025-10-23 University Of Washington Smart mhc: a de-novo designed platform for soluble expression of peptide-receptive class-i mhc in e. coli

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098448A1 (en) * 2001-06-04 2002-12-12 Human Genome Sciences, Inc. Methods and compositions for modulating ace-2 activity
KR20230017215A (ko) * 2020-05-27 2023-02-03 유니버시티 오브 워싱턴 드 노보 설계한 단백질 스위치에 기반한 모듈형의 일반화 가능한 바이오센서 플랫폼

Also Published As

Publication number Publication date
JP2023542453A (ja) 2023-10-10
US20230250134A1 (en) 2023-08-10
CN116209672A (zh) 2023-06-02
JP2025170319A (ja) 2025-11-18
EP4182027A1 (en) 2023-05-24
KR20230038485A (ko) 2023-03-20
WO2022015418A1 (en) 2022-01-20

Similar Documents

Publication Publication Date Title
US12171827B2 (en) Nucleic acid vaccine against the SARS-CoV-2 coronavirus
US20230250134A1 (en) SARS-COV-2 inhibitors
Zhang et al. Advances in developing ACE2 derivatives against SARS-CoV-2
JP7094103B2 (ja) インフルエンザウイルスワクチンおよびその使用
JP7554837B2 (ja) 可溶性ａｃｅ２及び融合タンパク質、並びにその適用
JP2022530439A (ja) 組換えインフルエンザ抗原
JP2017521425A (ja) インフルエンザウイルスワクチンおよびその使用
CN101472606A (zh) 用于治疗黄病毒感染的方法、分子及用途
JP2015532269A (ja) アルテリウイルス
WO2023039667A1 (en) Multivalent polypeptide constructs capable of binding viral spike proteins and methods of using the same
Isaacs et al. A nanobody-based therapeutic targeting Nipah virus limits viral escape
WO2026021236A1 (zh) 可抑制类mers冠状病毒感染的多肽及其应用
CA3181996A1 (en) Sars-cov-2 inhibitors
Case et al. Ultrapotent miniproteins targeting the receptor-binding domain protect against SARS-CoV-2 infection and disease in mice
RU2837537C1 (ru) Растворимый апф2, его слитый белок и способы их применения
KR102812522B1 (ko) Covid-19 유전자 백신용 dna 단편 및 이를 포함한 유전자 백신용 조성물
US20240035012A1 (en) Engineered ace2 oligomers and uses thereof
WO2025101453A1 (en) De novo design of potent minibinder antagonists of il-6r, gp130, and il1-r1
AU2024347309A1 (en) Reagents and methods for preventing, treating or limiting henipavirus infection
WO2025064372A1 (en) Reagents and methods for preventing, treating or limiting henipavirus infection
WO2024130083A1 (en) Modified measles viruses for treating coronavirus infections
CN117915936A (zh) 作为sars-cov-2抗病毒物的脂质肽融合抑制剂
EP4221747A2 (en) Clec2 fusion protein and uses thereof